Dannielle came to LGO from Eli Lilly and Co. and afterwards joined McKinsey & Co.,in its operations practice. After departing McKinsey, Dannielle held various leadership positions at Novartis and its subsidiaries where her responsibilities included developing the strategic direction and driving product transformation. After Novartis, Dannielle held roles including Chief Executive Officer at Rubius Therapeutics. In 2023 Dannielle joined COUR Pharma as Chief Operating Officer.
I value what the program taught me. I received broad exposure and built relationships for a lifetime. Through McKinsey, I was able to further leverage the skills and experiences from MIT and codify classroom concepts. I think my mentality is characteristic of many LGOs. At the core we are passionate about improving operations and driving organizations to be the best in their field.